NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application

Biotransformations of Anticancer Ruthenium(III) Complexes: An X-Ray Absorption Spectroscopic Study

(2013) Aviva Levina et al.   CHEMISTRY-A EUROPEAN JOURNAL

The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo

(2013) Petra Heffeter et al.   EUROPEAN JOURNAL OF CANCER

Nanoformulation Improves Activity of the (pre)Clinical Anticancer Ruthenium Complex KP1019

(2013) P. Heffeter et al.   Journal of Biomedical Nanotechnology

X-ray Absorption Near Edge Structure Spectroscopy to Resolve the in Vivo Chemistry of the Redox-Active Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019)

(2013) Alfred A. Hummer et al.   JOURNAL OF MEDICINAL CHEMISTRY

Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells

(2012) Jade B. Aitken et al.   Metallomics

Anticancer Activity of Metal Complexes: Involvement of Redox Processes

(2011) Ute Jungwirth et al.   ANTIOXIDANTS & REDOX SIGNALING

Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting

(2011) Min Ni et al.   BIOCHEMICAL JOURNAL

Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019

(2011) Caroline Bartel et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Approaching tumour therapy beyond platinum drugs

(2011) A. Bergamo et al.   JOURNAL OF INORGANIC BIOCHEMISTRY

LC– and CZE–ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(iii)] (KP1339) in mouse plasma

(2011) Anna K. Bytzek et al.   Metallomics

Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin

(2011) Michael Groessl et al.   Metallomics

Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339

(2010) Petra Heffeter et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry

(2010) Michael Groessl et al.   JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study

(2009) Frederike Lentz et al.   ANTI-CANCER DRUGS

KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients

(2008) Christian G. Hartinger et al.   CHEMISTRY & BIODIVERSITY

Resistance against novel anticancer metal compounds: Differences and similarities

(2008) P HEFFETER et al.   DRUG RESISTANCE UPDATES

Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles

(2008) Felix Kratz   JOURNAL OF CONTROLLED RELEASE

Electron-transfer activated metal-based anticancer drugs

(2006) Erwin Reisner et al.   INORGANICA CHIMICA ACTA